Published in TB and Outbreaks Week, June 29th, 1998
For this reason, researchers are seeking new therapies that have a broader antibacterial spectrum of activity while maintaining a high safety profile.
Preliminary data presented at the meeting suggested that a new methoxyquinolone antibiotic, BAY 12-8039 (proposed name: moxifloxacin), might meet these criteria as it shows promise in the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.